Pharmaceutical company Eli Lilly and Company (NYSE:LLY) on Thursday announced a USD1bn expansion of its manufacturing site in Limerick, Ireland, to increase production of biologic active ingredients.

The company has also completed an USD800m expansion of its facility in Kinsale, Ireland.

These investments are part of Lilly's broader manufacturing expansion strategy, with over USD20bn committed to new facilities since 2020. The Limerick expansion will support production of Alzheimer's disease treatments and other biologic medicines, while the Kinsale facility will focus on diabetes and obesity medications.

Once completed, the Limerick site will operate with 35% lower energy intensity, use 40% less water and generate 15% less waste than traditional biopharmaceutical manufacturing processes. In Kinsale, Lilly has a 26-acre solar farm which powers a significant portion of the facility.